Research and Development

In its internal research and development efforts, Selvita focuses on oncology.

The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor, which has recently received FDA acceptance to enter the clinical development and is intended to enter the clinic in Q4 2016.

The second most advanced program is SEL120, a first-in-class small molecule inhibitor of CDK8 with potential use in hematological malignancies, colorectal cancer and breast cancer.

Selvita Early Discovery programs include:  Immunooncology platform – small molecule GCN2 inhibitors and STING agonists, Eptheron – an oncology platform with an aim to develop novel molecules specifically targeting certain epigenetic and metabolic abnormalities in cancer, as well as an early discovery stage programs targeting SHMT2 and novel kinase targets.